Susquehanna International Group, LLP Astria Therapeutics, Inc. Call Options Transaction History

Susquehanna International Group, LLP

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 07, 2024	BUY	$6.99 - $16.69 $2.96 Million - $7.08 Million	424,100 New	424,100 $5.97 Million
Q2 2023 Aug 11, 2023	SELL	$8.33 - $13.72 $14,161 - $23,324	-1,700 Reduced 9.55%	16,100 $134,000
Q1 2023 May 16, 2023	BUY	$11.2 - $15.79 $199,360 - $281,062	17,800 New	17,800 $236,000
Q2 2022 Aug 15, 2022	SELL	$2.46 - $6.96 $291,756 - $825,456	-118,600 Reduced 65.71%	61,900 $186,000
Q1 2022 May 16, 2022	SELL	$3.92 - $7.1 $141,120 - $255,600	-36,000 Reduced 16.63%	180,500 $1.21 Million
Q4 2021 Feb 14, 2022	BUY	$5.08 - $8.62 $999,744 - $1.7 Million	196,800 Added 998.98%	216,500 $1.17 Million
Q3 2021 Nov 15, 2021	BUY	$7.32 - $12.9 $144,204 - $254,130	19,700 New	19,700 $174,000

107

48.6M

48K

9.3K

Ticker ATXS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 15,178,000
Market Cap $142M
Description
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.